Double-strand adeno-associated virus-mediated exendin-4 expression in salivary glands is efficient in a diabetic rat model

Diabetes Research and Clinical Practice

Volumn 103, Issue 3, 2014, Pages 466-473

  Wang, Junhong ^a   Wang, Feng ^b   Xu, Jing ^a   Ding, Shimei ^a   Guo, Yonghong ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adeno associated virus; Diabetes mellitus; Exendin 4; Salivary glands

Indexed keywords

ADENO-ASSOCIATED VIRUS; DIABETES MELLITUS; EXENDIN-4; SALIVARY GLANDS;

ANIMALS; BLOOD GLUCOSE; DEPENDOVIRUS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; GLUCAGON-LIKE PEPTIDE 1; HEK293 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOENZYME TECHNIQUES; INSULIN; MICE; NIH 3T3 CELLS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; SALIVARY GLANDS; VENOMS;

EID: 84898909180     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.12.006     Document Type: Article

References (43)

1. Kim S.W. Polymeric gene delivery for diabetic treatment. Diabetes Metab J 2011, 35:317-326.
2. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003, 278:471-478.
3. Brubaker P.L. Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology 2010, 151:1984-1989.
4. Ahren B. The future of incretin-based therapy: novel avenues-novel targets. Diabetes Obes Metab 2011, 13(Suppl 1):158-166.
5. Verspohl E.J. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009, 124:113-138.
6. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009, 23:463-477.
7. Dicembrini I., Pala L., Rotella C.M. From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. Exp Diabetes Res 2011, 2011:898913.
8. Srivastava A. Adeno-associated virus-mediated gene transfer. J Cell Biochem 2008, 105:17-24.
9. Stieger K., Le Meur G., Lasne F., Weber M., Deschamps J.Y., Nivard D., et al. Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther 2006, 13:967-975.
10. Niemeyer G.P., Herzog R.W., Mount J., Arruda V.R., Tillson D.M., Hathcock J., et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009, 113:797-806.
11. Daya S., Berns K.I. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008, 21:583-593.
12. Mandel R.J. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther 2010, 12:240-247.
13. Bainbridge J.W., Smith A.J., Barker S.S., Robbie S., Henderson R., Balaggan K., et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008, 358:2231-2239.
14. Diaz-Nido J. NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease. Curr Opin Invest Drugs 2010, 11:813-822.
15. Simonelli F., Maguire A.M., Testa F., Pierce E.A., Mingozzi F., Bennicelli J.L., et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010, 18:643-650.
16. Voutetakis A., Bossis I., Kok M.R., Zhang W., Wang J., Cotrim A.P., et al. Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders. J Endocrinol 2005, 185:363-372.
17. He X., Goldsmith C.M., Marmary Y., Wellner R.B., Parlow A.F., Nieman L.K., et al. Systemic action of human growth hormone following adenovirus-mediated gene transfer to rat submandibular glands. Gene Ther 1998, 5:537-541.
18. Adriaansen J., Perez P., Zheng C., Collins M.T., Baum B.J. Human parathyroid hormone is secreted primarily into the bloodstream after rat parotid gland gene transfer. Hum Gene Ther 2011, 22:84-92.
19. Samuni Y., Baum B.J. Gene delivery in salivary glands: from the bench to the clinic. Biochim Biophys Acta 2011, 1812:1515-1521.
20. Bertilsson G., Patrone C., Zachrisson O., Andersson A., Dannaeus K., Heidrich J., et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008, 86:326-338.
21. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001, 50:537-546.
22. Rotella C.M., Pala L., Mannucci E. Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J Endocrinol Invest 2005, 28:746-758.
23. Monami M., Marchionni N., Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009, 160:909-917.
24. Schnabel C.A., Wintle M., Kolterman O. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manage 2006, 2:69-77.
25. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000, 141:1936-1941.
26. Yu Y., Jang W., Xin Y. NT4 a NAP prokaryotic expression vector construction and in escherichia coli expression. J Neurol 2004, 37:260-261.
27. Berns K.I., Giraud C. Biology of adeno-associated virus. Curr Top Microbiol Immunol 1996, 218:1-23.
28. Afione S.A., Wang J., Walsh S., Guggino W.B., Flotte T.R. Delayed expression of adeno-associated virus vector DNA. Intervirology 1999, 42:213-220.
29. Ferrari F.K., Samulski T., Shenk T., Samulski R.J. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996, 70:3227-3234.
30. McCarty D.M., Fu H., Monahan P.E., Toulson C.E., Naik P., Samulski R.J. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003, 10:2112-2118.
31. Thomas C.E., Storm T.A., Huang Z., Kay M.A. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 2004, 78:3110-3122.
32. Di Pasquale G., Dicembrini I., Raimondi L., Pagano C., Egan J.M., Cozzi A., et al. Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes. PLoS One 2012, 7:e40074.
33. Kagami H., O'Connell B.C., Baum B.J. Evidence for the systemic delivery of a transgene product from salivary glands. Hum Gene Ther 1996, 7:2177-2184.
34. Baum B.J., Berkman M.E., Marmary Y., Goldsmith C.M., Baccaglini L., Wang S., et al. Polarized secretion of transgene products from salivary glands in vivo. Hum Gene Ther 1999, 10:2789-2797.
35. Baum B.J., Wellner R.B., Zheng C. Gene transfer to salivary glands. Int Rev Cytol 2002, 213:93-146.
36. O'Connell B.C., Zheng C., Jacobson-Kram D., Baum B.J. Distribution and toxicity resulting from adenoviral vector administration to a single salivary gland in adult rats. J Oral Pathol Med 2003, 32:414-421.
37. Rowzee A.M., Perez-Riveros P.J., Zheng C., Krygowski S., Baum B.J., Cawley N.X. Expression and secretion of human proinsulin-b10 from mouse salivary glands: implications for the treatment of type I diabetes mellitus. PLoS One 2013, 8:e59222.
38. Vosters J.L., Roescher N., Illei G.G., Chiorini J.A., Tak P.P. TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice. Oral Dis 2012, 18:365-374.
39. Moss R.B., Rodman D., Spencer L.T., Aitken M.L., Zeitlin P.L., Waltz D., et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004, 125:509-521.
40. Kim D., MacConell L., Zhuang D., Kothare P.A., Trautmann M., Fineman M., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30:1487-1493.
41. Kim J.W., Kim K., Ahn Y., Jeong H., Ryu S., Lee S., et al. Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: a potential long-acting glucagon-like peptide-1 mimetic. BMB Rep 2010, 43:146-149.
42. Huang Y.S., Chen Z., Chen Y.Q., Ma G.C., Shan J.F., Liu W., et al. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. J Pept Sci 2008, 14:588-595.
43. Peyot M.L., Gray J.P., Lamontagne J., Smith P.J., Holz G.G., Madiraju S.R., et al. Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic beta-cells. PLoS One 2009, 4:e6221.